• 1
    Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 150212
  • 2
    Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 151320
  • 3
    de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 19952005
  • 4
    de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 114754
  • 5
    Sonpavde G, Attard G, Bellmunt J et al. The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature. Eur Urol 2011; 60: 2708
  • 6
    Mottet N, Bellmunt J, Bolla M et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011; 59: 57283
  • 7
    Beltran H, Beer TM, Carducci MA et al. New therapies for castration-resistant prostate cancer: efficacy and safety. Eur Urol 2011; 60: 27990
  • 8
    Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 41122
  • 9
    Antonarakis ES, Armstrong AJ. Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 2011; 14: 20618
  • 10
    Antonarakis ES, Eisenberger MA. Expanding treatment options for metastatic prostate cancer. N Engl J Med 2011; 364: 20558
  • 11
    Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 64674
  • 12
    Joniau S, Abrahamsson PA, Bellmunt J et al. Current vaccination strategies for prostate cancer. Eur Urol 2012; 61: 290306
  • 13
    Tanai C, Nokihara H, Yamamoto S et al. Characteristics and outcomes of patients with advanced non-small-cell lung cancer who declined to participate in randomised clinical chemotherapy trials. Br J Cancer 2009; 100: 103742
  • 14
    Lara PN Jr, Higdon R, Lim N et al. Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol 2001; 19: 172833
  • 15
    Corrie P, Shaw J, Harris R. Rate limiting factors in recruitment of patients to clinical trials in cancer research: descriptive study. BMJ 2003; 327: 3201
  • 16
    Go RS, Frisby KA, Lee JA et al. Clinical trial accrual among new cancer patients at a community-based cancer center. Cancer 2006; 106: 42633
  • 17
    Tanai C, Nakajima TE, Nagashima K et al. Characteristics and outcomes of patients with advanced gastric cancer who declined to participate in a randomized clinical chemotherapy trial. J Oncol Pract 2011; 7: 14853
  • 18
    Jenkins V, Fallowfield L. Reasons for accepting or declining to participate in randomized clinical trials for cancer therapy. Br J Cancer 2000; 82: 17838
  • 19
    Albrecht TL, Eggly SS, Gleason ME et al. Influence of clinical communication on patients' decision making on participation in clinical trials. J Clin Oncol 2008; 26: 266673
  • 20
    Wright JR, Whelan TJ, Schiff S et al. Why cancer patients enter randomized clinical trials: exploring the factors that influence their decision. J Clin Oncol 2004; 22: 431218
  • 21
    Braunholtz DA, Edwards SJ, Lilford RJ. Are randomized clinical trials good for us (in the short term)? Evidence for a ‘trial effect’. J Clin Epidemiol 2001; 54: 21724
  • 22
    Kelly WK, Halabi S, Carducci MA et al. A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): survival results of CALGB 90401. J Clin Oncol 2012; 30: 153440
  • 23
    Sinibaldi VJ, Elza-Brown K, Schmidt J et al. Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma. Am J Clin Oncol 2006; 29: 3958
  • 24
    Beer TM, Eilers KM, Garzotto M, Egorin MJ, Lowe BA, Henner WD. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol 2003; 21: 1238
  • 25
    Savarese DM, Halabi S, Hars V et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol 2001; 19: 250916
  • 26
    Jameson MB, Thompson PI, Baguley BC et al. Phase I/II Trials Committee of Cancer Research UK. Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Br J Cancer 2003; 88: 184450
  • 27
    Lin J, Sinibaldi VJ, Carducci MA et al. Phase I trial with a combination of docetaxel and (153)Sm-lexidronam in patients with castration-resistant metastatic prostate cancer. Urol Oncol 2011; 29: 6705
  • 28
    Higano C, Saad F, Somer B et al. A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC). Genitourinary Cancers Symposium 2009; Abstract LBA150
  • 29
    Hudes GR, Tagawa S, Whang Y et al. A phase I study of CNTO 328, an anti-interleukin (IL)-6 monoclonal antibody combined with docetaxel (T) in subjects with metastatic castration-resistant prostate cancer (CRPC). Genitourinary Cancers Symposium 2009; Abstract 164
  • 30
    Scher HI, Halabi S, Tannock I et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 114859
  • 31
    Dinse GE, Lagakos SW. Nonparametric estimation of lifetime and disease onset distributions from incomplete observations. Biometrics 1982; 38: 92132
  • 32
    Karrison T. Confidence intervals for median survival times under a piecewise exponential model with proportional hazards covariate effects. Stat Med 1996; 15: 17182
  • 33
    Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 22847
  • 34
    Peppercorn JM, Weeks JC, Cook EF, Joffe S. Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet 2004; 363: 26370
  • 35
    Link MP, Goorin AM, Miser AW et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986; 314: 16006
  • 36
    Davis S, Wright PW, Schulman SF et al. Participants in prospective, randomized clinical trials for resected non-small cell lung cancer have improved survival compared with nonparticipants in such trials. Cancer 1985; 56: 171018
  • 37
    Halabi S, Small EJ, Kantoff PW et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003; 21: 12327
  • 38
    Armstrong AJ, Garrett-Mayer E, de Wit R, Tannock I, Eisenberger M. Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clin Cancer Res 2010; 16: 20311
  • 39
    Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF, Eisenberger M. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 2007; 13: 6396403